A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment With Trastuzumab Combined With Parezumab
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Early-stage Breast Cancer|HER2-positive Breast Cancer|Adjuvant Treatment After Trastuzumab|RCB Classification 1-2|Neratini
Interventions: DRUG: Trastuzumab and nelatinib|DRUG: Trastuzumab and Parstuzumab
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University